Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of antiinflammatory drugs with a fourth indication Bronchopulmonary Dysplasia.

Amsterdam the Netherlands Â6 November 2018 The Cell Factory in collaboration with the University of Padova Italy has completed preclinical invivo tests of the CFMEV132 drug candidate for the treatment of bronchopulmonary dysplasia BPD. BPD is a severe...